[Five years treatment of advanced solid malignomas with a combination of four cytostatic drugs (author's transl)].
132 patients with advanced solid malignomas were treated with a combination of four cytostatic drugs (vinblastine, amethopterine, 5-fluorouracil and cyclophosphamid) given on one day. This was repeated once every 2-3 weeks. In every case the diagnosis was made histologically and the tumour was staged according to the TNM-system. The treatment of breast and ovarian cancer brought the best results, improved by a synchronisation therapy. Good results were achieved also in the treatment of special kind of sarcomas and of carcinoma of the urine bladder. The general condition of patients with colon carcinoma could be improved in about 30%. Only one patient died by drug-induced pancytopenia, otherwise severe side-effects were not noted. Before beginning the therapy the cell-mediated immunity of 31 patients was tested by skin-tests with tuberkulin purified protein derivative (PPD) and dinitrochlorbenzole (DNCB). Before and during cytostatic therapy PPD reactions were proven by 23 patients. In accordance to other authors we found that cell-mediated immunity is decreased in the advanced stage of malignoma. Further we noted that delayed hypersensitivity and the number of lymphocytes and monocytes in peripherel blood are important to prognosis and course in patients with cancer.
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy; D014747:Vinblastine / Q000627:therapeutic use*
D014747:Vinblastine; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate
Fünf Jahre zytostatische Stosstherapie mit einer Viererkombination bei fortgeschrittenen soliden Malignomen